Emergent BioSolutions' (EBS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Emergent BioSolutions (NYSE:EBS - Free Report) in a research note published on Friday,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Emergent BioSolutions' Q1 2026 earnings at $0.87 EPS, Q2 2026 earnings at $1.04 EPS, Q3 2026 earnings at $1.11 EPS and Q4 2026 earnings at $0.81 EPS.

Separately, StockNews.com downgraded Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th.

Emergent BioSolutions Stock Down 4.2 %

EBS stock traded down $0.24 during mid-day trading on Friday, hitting $5.49. 843,175 shares of the company were exchanged, compared to its average volume of 2,618,371. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a 1-year low of $1.82 and a 1-year high of $15.10. The firm's 50 day simple moving average is $8.41 and its 200 day simple moving average is $8.72. The firm has a market cap of $298.31 million, a P/E ratio of -1.34 and a beta of 1.80.

Remove Ads

Emergent BioSolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.40. The business had revenue of $194.70 million for the quarter, compared to analyst estimates of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period last year, the business posted ($0.77) earnings per share. On average, sell-side analysts predict that Emergent BioSolutions will post -0.63 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Neal Franklin Fowler sold 35,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the sale, the director now owns 101,100 shares in the company, valued at $589,413. This represents a 25.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 1.20% of the company's stock.

Institutional Trading of Emergent BioSolutions

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. increased its stake in shares of Emergent BioSolutions by 23.4% during the 4th quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company's stock worth $20,437,000 after purchasing an additional 404,667 shares during the last quarter. State Street Corp grew its holdings in Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company's stock worth $15,960,000 after purchasing an additional 1,713,200 shares during the period. Invesco Ltd. increased its position in Emergent BioSolutions by 70.9% during the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock worth $14,722,000 after buying an additional 638,995 shares during the last quarter. Millennium Management LLC raised its stake in Emergent BioSolutions by 83.0% in the fourth quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company's stock valued at $14,167,000 after buying an additional 671,947 shares during the period. Finally, Oak Hill Advisors LP acquired a new stake in shares of Emergent BioSolutions in the third quarter valued at approximately $9,296,000. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.